1. Home
  2. MAXN vs BTAI Comparison

MAXN vs BTAI Comparison

Compare MAXN & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Maxeon Solar Technologies Ltd.

MAXN

Maxeon Solar Technologies Ltd.

HOLD

Current Price

$2.96

Market Cap

52.2M

Sector

Technology

ML Signal

HOLD

Logo BioXcel Therapeutics Inc.

BTAI

BioXcel Therapeutics Inc.

HOLD

Current Price

$1.81

Market Cap

43.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MAXN
BTAI
Founded
2019
2017
Country
Singapore
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
52.2M
43.7M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
MAXN
BTAI
Price
$2.96
$1.81
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$26.67
AVG Volume (30 Days)
47.4K
644.4K
Earning Date
03-06-2026
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$176,414,000.00
$752,000.00
Revenue This Year
$100.37
N/A
Revenue Next Year
$24.61
$265.60
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.49
$1.17
52 Week High
$6.76
$8.08

Technical Indicators

Market Signals
Indicator
MAXN
BTAI
Relative Strength Index (RSI) 47.58 46.07
Support Level $2.70 $1.85
Resistance Level $3.17 $2.08
Average True Range (ATR) 0.16 0.15
MACD -0.01 0.00
Stochastic Oscillator 60.14 42.45

Price Performance

Historical Comparison
MAXN
BTAI

About MAXN Maxeon Solar Technologies Ltd.

Maxeon Solar Technologies Ltd is engaged in the manufacturing and marketing of premium solar technology. It owns and operates solar cell and panel manufacturing facilities located in Malaysia, Mexico, and the Philippines. The company's primary products are the Maxeon line of interdigitated back contact (IBC) solar cells and panels, and the Performance line (formerly, P-Series) of shingled solar cells and panels. the Maxeon line of solar panels are the highest-efficiency solar panels on the market with an aesthetically pleasing design, and the Performance line of solar panels offers a high-value and cost-effective solution. It is targeted at residential and small-scale commercial customers across the globe. The company derives its revenue from the United States, Italy, and Rest of world.

About BTAI BioXcel Therapeutics Inc.

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

Share on Social Networks: